Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number NCT03277196 VX-770-126

    This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.

    • Age:

      0 days to 24 months

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      18

    • Length of Participation:

      128 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: Multiple care centres across the US

    Phase 2 study of lenabasum in people with CF ages 12 and older (Corbus JBT101-CF-002) , protocol number NCT03451045 JBT101-CF-002

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug lenabasum and will use a placebo control.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number Galapagos GLPG2222-CL-202

    This study will look at two different dose levels of GLPG2222. The study is placebo-controlled, which means that some participants will receive the study drug and others will receive a placebo. Participants will receive either the study drug or the placebo for 29 days and will be in the study for six to 10 weeks. Researchers will test the drug's safety and effectiveness by monitoring adverse events and other measures.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      5

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    Rare Mutation Cell Collection (RARE) , protocol number NCT 03161808 NCT 03161808

    This study is taking place at multiple care centres across the US. Researchers will collect and make available for study cells from people with rare CFTR mutations.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      8

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA, Australia, Europe

    Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor , protocol number NCT02549451 VX15-809-110

    Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

    • Age:

      6-11 years and 12 years and older

    • Mutation(s):

      Homozygous for the F508del-CFTR Mutation

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Phase 1Bstudy of inhaled AZD5634 in adults with CF , protocol number NCT02950805

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the inhaled drug AZD5634 in adults with CF.

    • Age:

      18 - 60 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      4

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis. , protocol number SAVARA SAV005

    This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

    • Age:

      6 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30-100%

    • Number of Visits:

      8

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor , protocol number NCT02412111 VX14-661-109

    This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

    • Age:

      12 years and older

    • Mutation(s):

      Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive

    • FEV1% Predicted:

      FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: Multiple care centres across the US

    RESULT: Study of liprotamase non-porcine enzymes , protocol number NCT03051490

    This study evaluated the effectiveness of liprotamase, a non-pig-derived pancreatic enzyme replacement therapy (PERT), as compared to Pancreaze®, a pig-derived PERT.

    • Age:

      7 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      17

    • Length of Participation:

      30 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Vertex Lumacaftor (VX-809) and Ivacaftor in children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation. , protocol number VX13-809-011b

    This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (Orkambi). This study was for younger children with CF who have two copies of the F508del CFTR mutation.

    • Age:

      6-11 years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      11

    • Length of Participation:

      27 weeks

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 165)
     |<  <  5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14  >  >|